Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
8.36
+0.18 (2.20%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Maze Therapeutics Revenue
In the year 2024, Maze Therapeutics had annual revenue of $167.50M.
Revenue (ttm)
$167.50M
Revenue Growth
n/a
P/S Ratio
0.12
Revenue / Employee
$1,340,000
Employees
125
Market Cap
368.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 167.50M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMAZE News
- 19 days ago - Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 2 months ago - Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - GlobeNewsWire
- 2 months ago - U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha
- 2 months ago - Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut - Reuters
- 2 months ago - Biotech firm Maze Therapeutics raises $140 million in US IPO - Reuters
- 2 months ago - Maze Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 2 months ago - Maze Therapeutics targets up to $728 mln valuation in US IPO - Reuters
- 3 months ago - Maze Therapeutics Seeks IPO For Trials Ramp-Up - Seeking Alpha